EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy

J Lupberger, MB Zeisel, F Xiao, C Thumann, I Fofana, L Zona, Christopher Davis, Christopher Mee, M Turek, S Gorke, C Royer, B Fischer, MN Zahid, D Lavillette, J Fresquet, FL Cosset, SM Rothenberg, T Pietschmann, AH Patel, P PessauxM Doffoel, W Raffelsberger, O Poch, Jane McKeating, L Brino, TF Baumert